In a major institutional block trade that caught the attention of domestic and global capital markets, Japanese technology conglomerate SoftBank pared its equity exposure in omnichannel eyewear major Lenskart Solutions, offloading a 1.56 per cent holding for roughly ₹1,896 crore. The secondary sale was executed on Friday across multiple block tranches on the Bombay Stock Exchange, highlighting continued portfolio realignment and capital monetization by late-stage venture backers following rapid expansion across India's consumer retail landscape. The transaction witnessed strong demand from top-tier institutional accounts, with American investment banking powerhouse Goldman Sachs stepping in as the single largest buyer.
Exchange disclosures released via BSE block deal logs showed that SoftBank executed the stake sale through its investment arm, SVF II Lightbulb (Cayman) Limited. The entity offloaded 2.72 crore equity shares of the Gurugram-headquartered eyewear company in ten discrete tranches at an identical price of ₹697.15 per share, yielding an aggregate transaction consideration of ₹1,896.24 crore. Following the partial divestment, SoftBank’s aggregate equity holding in Lenskart dropped from 7.27 per cent down to 5.71 per cent. Despite the sizeable block hitting the secondary window, strong absorption by marquee funds ensured that the counter weathered the volume comfortably, with shares of Lenskart advancing by nearly one per cent on Friday to close at ₹724.70 apiece.
The block deal saw participation from a diverse coalition of thirteen domestic and global asset managers, mutual funds, and sovereign wealth entities that scooped up the shares sold by SoftBank. Leading the charge on the buy side was Goldman Sachs, which purchased 91.84 lakh shares in a transaction valued at over ₹640 crore. Close behind was French financial services firm Societe Generale, through its ODI arm, securing 89.44 lakh shares for approximately ₹623.53 crore. United States-based asset manager William Blair Investment Management also accumulated an aggregate 11.1 lakh shares across several schemes, deploying around ₹77.43 crore. On the domestic front, top institutional vehicles including Kotak Mahindra Mutual Fund, UTI Mutual Fund, and HDFC Life Insurance Company added the stock to their portfolios alongside international participants like Norway's sovereign fund Norges Bank, BNP Paribas Financial Markets, The Northern Trust Company, and municipal pension retirement systems from Chicago and Texas.
The strong institutional appetite for Lenskart equity coincided with robust quarterly operational numbers published by the eyewear manufacturer and retailer earlier in the week. For the second quarter of the fiscal year, Lenskart delivered a 122 per cent year-on-year surge in consolidated net profit, reaching ₹227.08 crore against ₹102.22 crore in the corresponding period of the previous year. Topline performance demonstrated sustained momentum, with revenue from operations expanding by 35.7 per cent to touch ₹2,845.03 crore, driven by buoyant domestic consumption and steady international footprint growth. The company’s core Indian retail network continued to serve as the chief revenue driver, generating ₹1,668 crore during the quarter while product margins expanded to 64 per cent, underscoring resilient unit economics and strong operational efficiencies across its integrated supply chain.
Co-founded by Peyush Bansal, Amit Chaudhary, and Sumeet Kapahi, Lenskart has grown into an international retail presence spanning hundreds of stores across India, Southeast Asia, and the Middle East, while backing its physical network with robotic manufacturing hubs and an agile online platform. SoftBank originally entered the cap table as an anchor growth investor, providing primary capital that accelerated Lenskart's manufacturing automation and international retail footprint. For growth funds like SoftBank Vision Fund, phased block sales on public exchanges represent typical portfolio rebalancing maneuvers, allowing fund managers to return liquidity to limited partners while maintaining a substantial minority holding to capture future enterprise value.
Concurrently, secondary markets witnessed significant promoter stake rebalancing across the healthcare sector on the same day. Promoters of active pharmaceutical ingredient manufacturer Alivus Life Sciences, formerly known as Glenmark Life Sciences, offloaded a 2.31 per cent equity stake through open-market transactions. Detergent-to-chemicals conglomerate Nirma, which holds promoter control in Alivus, divested 28.46 lakh shares for approximately ₹390 crore at an execution price of ₹1,370 per share. Domestic institutional vehicles, including Bandhan Mutual Fund, alongside private investment funds like Mukul Agrawal-backed Param Capital and Norges Bank, absorbed the divestment block, though shares of Alivus drifted lower by around two per cent to settle near ₹1,472 following the trade.
The successful closure of SoftBank’s ₹1,896 crore divestment in Lenskart highlights the ongoing depth and maturity of the Indian equity market, where multi-thousand-crore block trades in high-growth consumer firms are seamlessly absorbed by institutional capital without causing structural price erosion. With major global asset managers, insurance institutions, and sovereign entities stepping forward to absorb early venture holdings, the counter’s performance reflects sustained investor conviction in profitable, tech-enabled consumer brands capable of sustaining multi-year margin expansion.



